Early recurrence factors in patients with stage III non‐small cell lung cancer treated with concurrent chemoradiotherapy
Abstract Background The clinical characteristics and risk factors for cancer recurrence have not been well evaluated regarding early recurrence in patients with unresectable locally advanced non‐small cell lung cancer (LA‐NSCLC) who receive concurrent chemoradiotherapy (CRT). The aim of this study w...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-12-01
|
| Series: | Thoracic Cancer |
| Subjects: | |
| Online Access: | https://doi.org/10.1111/1759-7714.14704 |
| _version_ | 1811290918728237056 |
|---|---|
| author | Yutaka Takahara Takuya Tanaka Yoko Ishige Ikuyo Shionoya Kouichi Yamamura Takashi Sakuma Kazuaki Nishiki Keisuke Nakase Masafumi Nojiri Ryo Kato Shohei Shinomiya Taku Oikawa Shiro Mizuno |
| author_facet | Yutaka Takahara Takuya Tanaka Yoko Ishige Ikuyo Shionoya Kouichi Yamamura Takashi Sakuma Kazuaki Nishiki Keisuke Nakase Masafumi Nojiri Ryo Kato Shohei Shinomiya Taku Oikawa Shiro Mizuno |
| author_sort | Yutaka Takahara |
| collection | DOAJ |
| description | Abstract Background The clinical characteristics and risk factors for cancer recurrence have not been well evaluated regarding early recurrence in patients with unresectable locally advanced non‐small cell lung cancer (LA‐NSCLC) who receive concurrent chemoradiotherapy (CRT). The aim of this study was to determine the clinical characteristics and risk factors of patients with stage III unresectable LA‐NSCLC treated with CRT who developed early recurrence. Methods We retrospectively reviewed the clinical records of 46 patients diagnosed with stage III unresectable LA‐NSCLC treated with CRT at our center between July 2012 and July 2021. A tumor proportion score (TPS) < 50% was defined as “low expression” and a TPS > 50% was defined as “high expression.” Results A total of 17 (37.0%) patients had a confirmed recurrence within 1 year of treatment. More patients had a lower body mass index in the early recurrence group than in the later recurrence group (p = 0.038). A higher number of patients in the late recurrence group underwent surgery after CRT (p = 0.036). Patients with a higher TPS were more likely to experience late recurrence than early recurrence (p = 0.001), whereas more patients with stage N3 disease were in the early recurrence group (p = 0.011). Multivariate analysis identified lower TPS expression as an independent risk factor for early recurrence after CRT. Overall survival was prolonged in the late recurrence group (p < 0.001). Conclusions A lower TPS may be a predictor of early recurrence after CRT in patients with LA‐NSCLC. These patients should be closely monitored for post‐treatment recurrence. |
| first_indexed | 2024-04-13T04:21:38Z |
| format | Article |
| id | doaj.art-bdb7c18e454343c4adf578a932fafbac |
| institution | Directory Open Access Journal |
| issn | 1759-7706 1759-7714 |
| language | English |
| last_indexed | 2024-04-13T04:21:38Z |
| publishDate | 2022-12-01 |
| publisher | Wiley |
| record_format | Article |
| series | Thoracic Cancer |
| spelling | doaj.art-bdb7c18e454343c4adf578a932fafbac2022-12-22T03:02:45ZengWileyThoracic Cancer1759-77061759-77142022-12-0113243451345810.1111/1759-7714.14704Early recurrence factors in patients with stage III non‐small cell lung cancer treated with concurrent chemoradiotherapyYutaka Takahara0Takuya Tanaka1Yoko Ishige2Ikuyo Shionoya3Kouichi Yamamura4Takashi Sakuma5Kazuaki Nishiki6Keisuke Nakase7Masafumi Nojiri8Ryo Kato9Shohei Shinomiya10Taku Oikawa11Shiro Mizuno12Department of Respiratory Medicine Kanazawa Medical University Kahoku‐gun JapanDepartment of Respiratory Medicine Kanazawa Medical University Kahoku‐gun JapanDepartment of Respiratory Medicine Kanazawa Medical University Kahoku‐gun JapanDepartment of Respiratory Medicine Kanazawa Medical University Kahoku‐gun JapanDepartment of Respiratory Medicine Kanazawa Medical University Kahoku‐gun JapanDepartment of Respiratory Medicine Kanazawa Medical University Kahoku‐gun JapanDepartment of Respiratory Medicine Kanazawa Medical University Kahoku‐gun JapanDepartment of Respiratory Medicine Kanazawa Medical University Kahoku‐gun JapanDepartment of Respiratory Medicine Kanazawa Medical University Kahoku‐gun JapanDepartment of Respiratory Medicine Kanazawa Medical University Kahoku‐gun JapanDepartment of Respiratory Medicine Kanazawa Medical University Kahoku‐gun JapanDepartment of Respiratory Medicine Kanazawa Medical University Kahoku‐gun JapanDepartment of Respiratory Medicine Kanazawa Medical University Kahoku‐gun JapanAbstract Background The clinical characteristics and risk factors for cancer recurrence have not been well evaluated regarding early recurrence in patients with unresectable locally advanced non‐small cell lung cancer (LA‐NSCLC) who receive concurrent chemoradiotherapy (CRT). The aim of this study was to determine the clinical characteristics and risk factors of patients with stage III unresectable LA‐NSCLC treated with CRT who developed early recurrence. Methods We retrospectively reviewed the clinical records of 46 patients diagnosed with stage III unresectable LA‐NSCLC treated with CRT at our center between July 2012 and July 2021. A tumor proportion score (TPS) < 50% was defined as “low expression” and a TPS > 50% was defined as “high expression.” Results A total of 17 (37.0%) patients had a confirmed recurrence within 1 year of treatment. More patients had a lower body mass index in the early recurrence group than in the later recurrence group (p = 0.038). A higher number of patients in the late recurrence group underwent surgery after CRT (p = 0.036). Patients with a higher TPS were more likely to experience late recurrence than early recurrence (p = 0.001), whereas more patients with stage N3 disease were in the early recurrence group (p = 0.011). Multivariate analysis identified lower TPS expression as an independent risk factor for early recurrence after CRT. Overall survival was prolonged in the late recurrence group (p < 0.001). Conclusions A lower TPS may be a predictor of early recurrence after CRT in patients with LA‐NSCLC. These patients should be closely monitored for post‐treatment recurrence.https://doi.org/10.1111/1759-7714.14704body mass indexchemoradiotherapyneoplasm recurrencenon‐small cell lung carcinomatumor proportion score |
| spellingShingle | Yutaka Takahara Takuya Tanaka Yoko Ishige Ikuyo Shionoya Kouichi Yamamura Takashi Sakuma Kazuaki Nishiki Keisuke Nakase Masafumi Nojiri Ryo Kato Shohei Shinomiya Taku Oikawa Shiro Mizuno Early recurrence factors in patients with stage III non‐small cell lung cancer treated with concurrent chemoradiotherapy Thoracic Cancer body mass index chemoradiotherapy neoplasm recurrence non‐small cell lung carcinoma tumor proportion score |
| title | Early recurrence factors in patients with stage III non‐small cell lung cancer treated with concurrent chemoradiotherapy |
| title_full | Early recurrence factors in patients with stage III non‐small cell lung cancer treated with concurrent chemoradiotherapy |
| title_fullStr | Early recurrence factors in patients with stage III non‐small cell lung cancer treated with concurrent chemoradiotherapy |
| title_full_unstemmed | Early recurrence factors in patients with stage III non‐small cell lung cancer treated with concurrent chemoradiotherapy |
| title_short | Early recurrence factors in patients with stage III non‐small cell lung cancer treated with concurrent chemoradiotherapy |
| title_sort | early recurrence factors in patients with stage iii non small cell lung cancer treated with concurrent chemoradiotherapy |
| topic | body mass index chemoradiotherapy neoplasm recurrence non‐small cell lung carcinoma tumor proportion score |
| url | https://doi.org/10.1111/1759-7714.14704 |
| work_keys_str_mv | AT yutakatakahara earlyrecurrencefactorsinpatientswithstageiiinonsmallcelllungcancertreatedwithconcurrentchemoradiotherapy AT takuyatanaka earlyrecurrencefactorsinpatientswithstageiiinonsmallcelllungcancertreatedwithconcurrentchemoradiotherapy AT yokoishige earlyrecurrencefactorsinpatientswithstageiiinonsmallcelllungcancertreatedwithconcurrentchemoradiotherapy AT ikuyoshionoya earlyrecurrencefactorsinpatientswithstageiiinonsmallcelllungcancertreatedwithconcurrentchemoradiotherapy AT kouichiyamamura earlyrecurrencefactorsinpatientswithstageiiinonsmallcelllungcancertreatedwithconcurrentchemoradiotherapy AT takashisakuma earlyrecurrencefactorsinpatientswithstageiiinonsmallcelllungcancertreatedwithconcurrentchemoradiotherapy AT kazuakinishiki earlyrecurrencefactorsinpatientswithstageiiinonsmallcelllungcancertreatedwithconcurrentchemoradiotherapy AT keisukenakase earlyrecurrencefactorsinpatientswithstageiiinonsmallcelllungcancertreatedwithconcurrentchemoradiotherapy AT masafuminojiri earlyrecurrencefactorsinpatientswithstageiiinonsmallcelllungcancertreatedwithconcurrentchemoradiotherapy AT ryokato earlyrecurrencefactorsinpatientswithstageiiinonsmallcelllungcancertreatedwithconcurrentchemoradiotherapy AT shoheishinomiya earlyrecurrencefactorsinpatientswithstageiiinonsmallcelllungcancertreatedwithconcurrentchemoradiotherapy AT takuoikawa earlyrecurrencefactorsinpatientswithstageiiinonsmallcelllungcancertreatedwithconcurrentchemoradiotherapy AT shiromizuno earlyrecurrencefactorsinpatientswithstageiiinonsmallcelllungcancertreatedwithconcurrentchemoradiotherapy |